The incidence of non-Hodgkin’s lymphomas, a group of heterogeneous lymphoproliferative disorders, has nearly doubled in the last several decades. Traditional treatment strategies have focused on surgery, chemotherapy, and radiation therapy. Despite treatment, resistance and recurrence rates remain high and the disease has been considered invariably fatal. In recent years, the introduction of new treatment options, especially biologic therapies, has increased survival rates. Although these therapies contribute to remission, they are not without toxicity. Innovative treatment options, including radioimmunotherapy and patient-specific cancer vaccines, that focus on specific molecular targets or engage the patient’s immune system are expected to further improve survival while producing minimal side effects. This symposium will review clinical studies of emerging therapies, appropriate patient selection criteria, and their place among traditional therapies such as chemotherapy, radiation, bone marrow transplantation, surgery and biological therapies.

Target Audience
The target audience for this educational symposium is physicians and other practitioners and scientists involved in the field of hematology, specifically those with an interest in the treatment of blood, lymphatic, and immunologic cancers.